BCL2 and ovarian carcinoma: Our findings agree with others in that the silencing of Bcl-2 improved sensitivity to cisplatin treatment in bladder cancer cells [22], melanoma cells [23], ovarian cancer cells [24], non-small lung cancer cells [25] and lung adenocarcinoma cells [26].